These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35849782)

  • 1. A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction.
    Stein S; Dooley K; Ubohla NV; Hochster HS
    Oncology (Williston Park); 2022 Jul; 36(7):414-419. PubMed ID: 35849782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-induced hypersensitivity reactions: risk factors and management.
    Selcuk A; Yıldız B
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2640-2645. PubMed ID: 37013782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
    Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
    Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study.
    Sohn KH; Kang DY; Kim JY; Lee SY; Lee KH; Han SW; Kang HR
    J Allergy Clin Immunol Pract; 2018; 6(5):1642-1648.e2. PubMed ID: 29454708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.
    Li M; Jiang C; Yang JW; Yu ZQ; Li W; Zhao L; Song QY; Zhang CL; Liu D
    Curr Med Sci; 2021 Aug; 41(4):827-831. PubMed ID: 34403109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin: Detection and Management of Hypersensitivity Reactions.
    Rogers BB; Cuddahy T; Briscella C; Ross N; Olszanski AJ; Denlinger CS
    Clin J Oncol Nurs; 2019 Feb; 23(1):68-75. PubMed ID: 30682002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure.
    Lee SY; Kang HR; Song WJ; Lee KH; Han SW; Cho SH
    Cancer Chemother Pharmacol; 2014 May; 73(5):1021-9. PubMed ID: 24696124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
    Wang AL; Patil SU; Long AA; Banerji A
    Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
    Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
    Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Desensitization to Oxaliplatin After a Single Initial Dose of Omalizumab in a Patient With Elevated IgE Levels.
    Penella J; Quan P; Carvallo A; Chopitea A; Sala P; García Del Barrio MA; Gastaminza G; Goikoetxea MJ
    J Investig Allergol Clin Immunol; 2020; 30(4):293-295. PubMed ID: 32101174
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypersensitivity to oxaliplatin: clinical features and risk factors.
    Parel M; Ranchon F; Nosbaum A; You B; Vantard N; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; Vial T; Trillet-Lenoir V; Freyer G; Berard F; Rioufol C
    BMC Pharmacol Toxicol; 2014 Jan; 15():1. PubMed ID: 24417770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
    Barroso-Sousa R; Vaz-Luis I; Di Meglio A; Hu J; Li T; Rees R; Sinclair N; Milisits L; Leone JP; Constantine M; Faggen M; Briccetti F; Block C; Partridge A; Burstein H; Waks AG; Tayob N; Trippa L; Tolaney SM; Hassett MJ; Winer EP; Lin NU
    Oncologist; 2021 Nov; 26(11):927-933. PubMed ID: 34472667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose.
    Stretz E; Oppel EM; Räwer HC; Chatelain R; Mastnik S; Przybilla B; Ruëff F
    Clin Exp Allergy; 2017 Dec; 47(12):1631-1639. PubMed ID: 28802075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early Detection of and Initial Response to Oxaliplatin-Related Hypersensitivity Reactions].
    Taniguchi J; Itonaga S; Kanazawa E; Murakami M; Saeki A; Hashimoto M
    Gan To Kagaku Ryoho; 2020 Jan; 47(1):61-65. PubMed ID: 32381864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review.
    Barbin F; Ghidini M; Panichi A; Tomasello G; Bareggi C; Galassi B; Denaro N; Ruatta F; Cauchi C; Rossino MG; Garrone O
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
    Park SJ; Lee KY; Park WS; Min SY
    Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of hypersensitivity reactions in patients on H1-receptor antagonists receiving oxaliplatin-based chemotherapy.
    Barrett C; Park SJ; Edmondson L; Monga D
    J Oncol Pharm Pract; 2022 Apr; 28(3):577-581. PubMed ID: 33789524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.